Annovis Bio (ANVS) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spero Therapeutics (SPRO) has outperformed Annovis Bio (ANVS) over the past year, losing 67.9% versus a loss of 81.2%. Over five years, SPRO leads with a -95.1% price change compared with -97.2% for ANVS. Annovis Bio is the larger company by market cap ($44.1 million vs $43.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | SPRO |
|---|---|---|
| Share price | $0.7113 | $0.742 |
| Market cap | $44.12M | $43.23M |
| 1-day change | -4.96% | -10.20% |
| YTD return | -79.44% | -68.15% |
| 1-year return | -81.23% | -67.88% |
| 5-year return | -97.24% | -95.09% |
| EPS (TTM) | $-1.55 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $66.80M |
| Revenue growth (YoY) | — | +39.24% |
| Net income (latest FY) | $-28.85M | $8.57M |
| Operating margin | — | 9.45% |
| Net margin | — | 12.83% |
| 52-week high | $5.50 | $3.08 |
| 52-week low | $0.62 | $0.73 |
| Distance from 52-week high | -87.07% | -75.91% |
| Analyst consensus | none | none |
| Avg. price target upside | +1376.17% | +573.85% |
| Average volume | 1.82M | 530.46K |
| Shares outstanding | 62.02M | 58.26M |
| Employees | 7 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SPRO has outperformed ANVS by 13.4 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
ANVS vs SPRO FAQ
Which is bigger, Annovis Bio or Spero Therapeutics?
Annovis Bio (ANVS) is larger, with a market capitalization of $44.12M compared with $43.23M for Spero Therapeutics (SPRO).
Which stock has performed better over the past year, ANVS or SPRO?
SPRO returned -67.88% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.